Advaxis

Advaxis

Employees:
90
Market Cap:
$302.35 million
Revenue:
$4 million
Net Income:
$-74.27 million
NASDAQ:
ADXS

Advaxis is an American company devoted to the discovery, development and commercialization of immunotherapies based on a technology platform which uses engineered Listeria monocytogenes (aka Lm).:1 The company is headquartered in Princeton, New Jersey and was incorporated in Delaware in 2006.:1 The Lm-based platform on which the companys products are based involves the use of attenuated Lm which secrete antigen/adjuvant fusion proteins and stimulate a patients immune system (specifically their T cells) to mount an immune response to the secreted antigen; if the antigen is specifically found on cancerous cells, then the result aims to be an effective immune response targeting and eliminating the cancer.:1 Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies.:1 Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. Wikipedia

Advaxis

Employees:
90
Market Cap:
$302.35 million
Revenue:
$4 million
Net Income:
$-74.27 million
NASDAQ:
ADXS

Advaxis is an American company devoted to the discovery, development and commercialization of immunotherapies based on a technology platform which uses engineered Listeria monocytogenes (aka Lm).:1 The company is headquartered in Princeton, New Jersey and was incorporated in Delaware in 2006.:1 The Lm-based platform on which the companys products are based involves the use of attenuated Lm which secrete antigen/adjuvant fusion proteins and stimulate a patients immune system (specifically their T cells) to mount an immune response to the secreted antigen; if the antigen is specifically found on cancerous cells, then the result aims to be an effective immune response targeting and eliminating the cancer.:1 Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies.:1 Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. Wikipedia

Feb 19, 5:01 PM

Our Lm Technology utilizes the efficiency of the entire immune system by teaching it to recognize the tumor as a threat, and by weakening the tumors defenses. Once educated by Lm Technology, the immune systemspecifically, its killer T cellsare enabled to do their job and work to destroy the cancer. http://www.advaxis.com/lm-technology/